166 related articles for article (PubMed ID: 37946262)
1. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA.
Jodele S; Dandoy CE; Aguayo-Hiraldo P; Lane A; Teusink-Cross A; Sabulski A; Mizuno K; Laskin BL; Freedman J; Davies SM
Blood; 2024 Mar; 143(12):1112-1123. PubMed ID: 37946262
[TBL] [Abstract][Full Text] [Related]
2. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
3. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
5. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
6. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT.
Mizuno K; Dandoy CE; Teusink-Cross A; Davies SM; Vinks AA; Jodele S
Blood Adv; 2022 Mar; 6(5):1454-1463. PubMed ID: 35008105
[TBL] [Abstract][Full Text] [Related]
9. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
10. Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study.
Svec P; Elfeky R; Galimard JE; Higham CS; Dalissier A; Quigg TC; Bueno Sanchez D; Han Lum S; Faraci M; Cole T; Pichler H; Benítez-Carabante MI; Horakova J; Gonzalez-Vicent M; Yanir A; Fagioli F; Wölfl M; von der Weid N; Protheroe R; Krivan G; Speckmann C; James B; Avcin SL; Bertrand Y; Verna M; Riha P; Patrick K; Cesaro S; Kalwak K; Bierings M; Büchner J; Mellgren K; Prohászka Z; Neven B; Lankester A; Corbacioglu S
Bone Marrow Transplant; 2023 Feb; 58(2):129-141. PubMed ID: 36333550
[TBL] [Abstract][Full Text] [Related]
11. Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation.
El-Bietar J; Warren M; Dandoy C; Myers KC; Lane A; Wallace G; Davies SM; Jodele S
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1994-2001. PubMed ID: 26150023
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
13. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
15. D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study.
Schoettler ML; French K; Harris A; Bryson E; Deeb L; Hudson Z; Obordo J; Chandrakasan S; Parikh S; Watkins B; Stenger E; Qayed M; Chonat S; Westbrook A; Switchenko J; Williams KM
Am J Hematol; 2024 Mar; 99(3):370-379. PubMed ID: 38164997
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease.
Bhunia N; Abu-Arja R; Bajwa RPS; Auletta JJ; Rangarajan HG
Pediatr Blood Cancer; 2019 Oct; 66(10):e27912. PubMed ID: 31264793
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.
Vasu S; Wu H; Satoskar A; Puto M; Roddy J; Blum W; Klisovic R; Andritsos L; Hofmeister C; Benson DM; Efebera Y; Jaglowski S; Penza S; Cohen D; Devine S; Cataland S
Bone Marrow Transplant; 2016 Sep; 51(9):1241-4. PubMed ID: 27064689
[No Abstract] [Full Text] [Related]
18. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
19. Use of Eculizumab in Thrombotic Microangiopathy Associated with Hematopoietic Stem Cell Transplantation.
Demircioglu S; Dogan A; Demir C
J Coll Physicians Surg Pak; 2021 Nov; 31(11):1359-1361. PubMed ID: 34689499
[TBL] [Abstract][Full Text] [Related]
20. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
